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The expression level of BAALC-associated microRNA
miR-3151 is an independent prognostic factor in younger
patients with cytogenetic intermediate-risk acute myeloid
leukemia
M Díaz-Beyá1,2, S Brunet2,3, J Nomdedéu2,3, A Cordeiro4, M Tormo5, L Escoda6, JM Ribera2,7, M Arnan8, I Heras9, D Gallardo10, J Bargay11,
MP Queipo de Llano12, O Salamero13, JM Martí14, A Sampol15, C Pedro16, M Hoyos3, M Pratcorona1,2, JJ Castellano4, M Nomdedeu1,2,
RM Risueño2, J Sierra2,3, M Monzó4, A Navarro4,18 and J Esteve1,2,17,18
Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by
cytogenetics and molecular profiling. In elderly patients (⩾60 years) with normal karyotype AML miR-3151 have been identified as a
prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we
have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML
(IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P= 0.0025), shorter leukemia-free
survival (P= 0.026) and higher cumulative incidence of relapse (P= 0.082). Moreover, in the multivariate analysis miR-3151 emerged
as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category.
Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with
low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both
markers (P= 0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA
signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic
stratification of younger patients with IR-AML.
Blood Cancer Journal (2015) 5, e352; doi:10.1038/bcj.2015.76; published online 2 October 2015
INTRODUCTION
The biological heterogeneity of acute myeloid leukemia (AML)
results in a markedly diverse prognosis and highly differential
sensitivity to current standard therapy. The most accurate
prognostic stratification is based on cytogenetics, further refined
with the analysis of several gene mutations.1–4 In cytogenetic
intermediate-risk AML (IR-AML), comprising ~ 50% of all AML
patients, the mutational status of NPM1, internal tandem
duplication of FLT3 (FLT3-ITD), and CEBPA defines molecular
subcategories with different biological risk and diverse
outcomes.2,4 Therefore, many current AML treatment protocols
adapt their therapeutic algorithm to this biological risk. None-
theless, despite several attempts to fine-tune stratification based
on these molecular subcategories, the prognosis of many patients
with IR-AML is still uncertain and the optimal post-remission
therapy is unclear.
Several studies have shown the importance of microRNA
(miRNA) deregulation in AML.5–7 Distinctive miRNA profiles have
been associated with specific cytogenetic subtypes: AML asso-
ciated with translocation t(8;21), t(15;17) or inv(16) and MLL-
rearranged AML;8,9 t(8;16) AML;10 and AML with specific gene
mutations,11 including NPM1,9,12 FLT39,13 and CEBPA.8–10,13–15 In
addition, several miRNAs have been associated with clinical
outcome.11 Three studies that included cytogenetically hetero-
geneous AML cohorts found that expression levels of miR-191 and
miR-199a,13 miR-196b16 and miR-212(ref. 16) were associated with
overall survival (OS). In patients with cytogenetically normal AML
(CN-AML) and high-risk molecular features, a 12-miRNA prognostic
signature was proposed by the CALGB group; this signature
included five members of the miR-181 family.13 The individual
prognostic value of miR-181a was later confirmed in a cohort of
CN-AML patients by the same group.17 miR-155 has also been
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described as a prognostic marker in both older and younger CN-
AML patients by the CALGB group.18 Our group has reported four
miRNAs (miR-196b, miR-644, miR-135a and miR-409-3p) with
prognostic value in IR-AML.19
miR-3151, which was first identified by massive sequencing
techniques,20,21 is located within the first intron of the BAALC
gene. In a CALGB study including only CN-AML patients older than
60 years, miR-3151 was identified as an independent prognostic
factor.22 In the same study, patients with overexpression of both
miR-3151 and BAALC had the worst outcome, while those with low
levels of both had the best outcome. Moreover, the authors
described an mRNA/miRNA profile associated with higher
miR-3151 expression. The same group later reported that
miR-3151 and BAALC were both regulated by SP1/NF-KB, while
BAALC expression (but not miR-3151) was regulated by the
transcription factor RUNX1. Moreover, TP53 was identified as a
target of miR-3151, and higher levels of miR-3151 induced
leukemogenesis in a murine model and reduced apoptosis and
chemosensitivity in AML cell lines.23
Although the CALGB study included only older patients with
CN-AML,22 grouping patients with CN-AML together with those
with other cytogenetic intermediate-risk alterations in the same
prognostic category seems to be warranted from the clinical
standpoint.2 Furthermore, younger patients have diverse options
for post-remission strategies, including the possibility of an
allogeneic hematopoietic stem cell transplantation, depending
on biological risk, highlighting a need for prognostic markers in
this group. Nevertheless, the prognostic value of miR-3151
expression has not been explored in younger IR-AML patients.
We have examined the effect of miR-3151 expression in 181




We selected patients with untreated, de novo IR-AML according to the MRC
classification3 and with available RNA samples at diagnosis for miRNA
analysis (Table 1). All patients provided their written informed consent in
accordance with the Declaration of Helsinki, and the Ethics Committee of
Hospital Clinic of Barcelona approved the study.
All 181 IR-AML patients were treated from 1994 to 2009 in any of 16
centers participating in three consecutive trials of intensive chemotherapy
for fit patients of the Spanish AML cooperative group CETLAM: AML-94
(n=9); AML-99 (NCT01716793) (n= 26); AML-03 (NCT01723657) (n=146).
Briefly, the induction regimen of AML-94 was ICE (idarubicin, standard-
dose cytarabine and etoposide), while in AML-99 and AML-03 it consisted
of one or two courses of IDICE (idarubicin, intermediate-dose cytarabine
and VP-16), with or without priming with G-CSF, respectively. All patients
achieving complete remission (CR) received an additional course of
chemotherapy with mitoxantrone and high-dose cytarabine, and then a
transplant decision was made. In protocols AML-99 and AML-03, an
autologous HSCT was planned for patients harboring a normal karyotype
without additional risk factors, whereas alloHSCT in first CR (CR1) was
recommended for the remaining patients with an available donor. Risk
factors considered for risk assignment were the need for two induction
courses to achieve CR, detectable minimal residual disease by flow
cytometry after intensification therapy (AML-03), and presence of FLT3-ITD
(AML-03). In AML-94, post-remission strategy (autoHSCT vs alloHSCT)
depended exclusively on the availability of an HLA-identical sibling.
Molecular analysis
NPM1 and FLT3-ITD mutations were assessed on genomic DNA as
previously described24,25 with labeled primers and analyzed by fragment
analysis (3130XL Genetic Analyzer, Applied Biosystems (AB), Foster City, CA,
USA). CEBPA mutations were analyzed as previously described.14,26
RNA extraction
Samples were obtained from bone marrow aspirates in 171 (94%) patients,
and from peripheral blood, with a minimum blast infiltration of 80%, in the
remaining 10 patients. Mononuclear cells were purified by Ficoll density
gradient centrifugation and total RNA was isolated using Trizol reagent
according to manufacturer’s protocol (Invitrogen, Paisley, UK). All patients
provided their written informed consent in accordance with the
Declaration of Helsinki, and the Ethics Committee of each participating
institution approved the study.
miRNA quantification
The expression of miR-3151 was analyzed using TaqMan MicroRNA Assay
(Applied Biosystems 243597_mat). Ten nanograms of total RNA were used
for miRNA quantification. TaqMan microRNA assays (AB) for miR-3151 were
used as previously described27 in an AB 7500 Sequence Detection System.
Relative quantification was calculated using 2-ΔΔCt. Normalization was
performed with RNU48 (Applied Biosystems 4427975). All experiments
were performed in triplicate.
We had previously performed a comprehensive miRNA expression
analysis, comprising 670 mature human miRNAs, in tumor samples from
the 78 out of the 181 patients10 using TaqMan Array Human MicroRNA Set
Cards v2.0 (AB).
mRNA expression analysis
cDNA was synthesized from 1000 ng of total RNA using TaqMan Reverse
Transcription Reagent Kit (Applied Biosystems). TaqMan Gene expression
assays (Applied Biosystems) were used to determine mRNA levels of BAALC
Table 1. Main clinical characteristics of patients included in the study
Intermediate risk AML n= 181




Median age, years (range) 51 (18–69)











Other intermediate-risk 50 (28%)
Molecular features n (%)
NPM1 mutation 79 (43%)
FLT3-ITD 68 (37%)
CEBPA biallelic mutation 8 (7%)





Complete response to induction regimen 83%
Overall survival (5- year) 42± 7%
Leukemia-free survival (5- year) 42± 8%
Cumulative incidence relapse (5- year) 45± 8%
Allogeneic HSCT in first CR 42 (23%)
Abbreviations: AML, acute myeloid leukemia; CR, complete remission;
HSCT, hematopoietic stem cell transplantation.
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(Hs00227249_m1) and GUSB (Hs00939627_m1), used as housekeeping
gene. Real-time PCR was performed in the ABI Prism 7500 Sequence
Detection System (Applied Biosystems). All samples for each gene were
run in triplicate and relative quantification was calculated using 2−ΔΔCt.
Normalization was performed with GUSB.
Molecularly defined prognostic subgroups in IR-AML
The presence or absence of FLT3-ITD, NPM1 and biallelic CEBPA mutations
have a strong prognostic impact in patients with IR-AML.2,4 According to
the European LeukemiaNet prognostic classification, patients with the
NPM1 mutation or the biallelic CEBPA mutation but without the FLT3-ITD
mutation, when associated to normal cytogenetics, comprise a favorable
genetic group—with better prognosis—while patients with the FLT3-ITD
mutation and/or without the NPM1 and the biallelic CEBPA mutation
comprise the intermediate-I and intermediate-II genetic groups. In the
present study, we have classified all IR-AML patients with NPM1 mutations
or biallelic CEBPA mutations but without FLT3-ITD mutations as the
favorable molecular (FAVmol) subgroup and all remaining IR-AML patients
as the unfavorable molecular (UNFAVmol) subgroup.
Clinical endpoints and statistical methods
Expression levels of miR-3151 and BAALC were correlated with patient
outcome. OS was calculated from diagnosis to death or last follow-up and
leukemia-free survival (LFS) from CR to relapse or death. Both OS and LFS
were estimated with the Kaplan–Meier method and comparisons among
subgroups of patients were performed using the log-rank test. Relapse risk
was calculated from CR to relapse and estimated using the cumulative
incidence of relapse (CIR) method computed with the cmprsk package for R
2.12 software (The R Foundation for Statistical Computing, http://www.R-
project.org/). The competing event in the relapse risk analysis was death
without relapse. Comparison of relapse risk between groups of patients was
performed using the Gray test.28 Characteristics between groups were
compared using the χ2-test and Fisher’s exact test, when applicable, for
categorical variables, and the t-test for continuous variables. Multivariate
analyses for OS and LFS were performed using the Cox proportional hazards
model including age (10-year intervals), gender, white blood cell count (WBC;
50×109/l increments) at diagnosis, mutational status of NPM1 and FLT3-ITD,
and miR-3151 and/or BAALC expression level. A multivariate analysis for CIR
was performed using the subdistribution regression model of Fine and Gray29
with the cmprsk package. The proportional hazard assumption was tested for
each variable by analyzing the Schoenfeld residuals. Kaplan–Meier survival
curves were then drawn for miR-3151 and BAALC expression predicted to
show a survival risk either above or below average risk, using the cut-off
points of miR-3151 and BAALC expression levels identified by MaxStat
package of R software (The R Foundation for Statistical Computing, http://
www.R-project.org/). All analyses were performed with SPSS v.20 (Chicago, IL,
USA) or R software version 2.12.2 (The R Foundation for Statistical Computing,
http://www.R-project.org/). Significance was set at ⩽0.05.
To identify miRNAs with significant differential expression correlated
with miR-3151 expression, data obtained from our previously identified
miRNA profile10 were analyzed using BRB Array Tools version 3.5.0 software
(Richard Simon & BRB-ArrayTools Development Team, http://linus.nci.nih.
gov/BRB-ArrayTools.html, National Cancer Institute, Bethesda, MD, USA)
and TIGR Multiexperiment viewer version 4.0 software (The Institute for
Genomic Research, and ArrayAssist software, Stratagene, http://www.tm4.
org/mev; Boston, MA, USA). A student’s t-test based on multivariate
permutation was performed with adjustment for multiple comparisons and
with random variance model. Differences between miRNAs were
considered statistically significant if the P-value was o0.01.
RESULTS
miR-3151 expression and clinical and molecular characteristics
miR-3151 was expressed with a variable expression level in the
group of AML samples analyzed, with a median expression level of
3.94 (0–9.78) (Figure 1). The expression of miR-3151 was not
significantly associated with any particular clinical feature,
including age, WBC, bone marrow blast proportion, or FAB
subtype, with the exception of NPM1 mutation. Thus, miR-3151
was more expressed among patients without NPM1 mutation and,
using the same cut-off level as identified by the MaxStat package
for prognostic purposes, patients with higher miR-3151 were more
likely to harbor a wild-type NPM1 configuration (80 vs 20%,
P= 0.009).
miR-3151 expression has independent prognostic value in
younger IR-AML patients
With a median follow-up of 8.4 years (range: 36-196 months)
among patients alive at last follow-up, the 181 IR-AML patients
had a CR rate of 83% and a 5-year OS, LFS and CIR of 42 ± 7, 42 ± 8
and 45 ± 8%, respectively. Figure 1a shows the optimal cut-off
level for miR-3151 expression as identified by the MaxStat
package. Patients with higher miR-3151 levels experienced a
worse outcome, with poorer OS and LFS (5-year OS: 15 ± 13 vs
46± 7%, P= 0.0025; 5-year LFS: 22 ± 18 vs 45 ± 7%, P= 0.026), and a
higher CIR (71 ± 20 vs 41.5 ± 8%, P= 0.082) compared with patients
with lower levels (Figures 1b–d). In contrast, miR-3151 expression
levels were not associated with the probability of attaining CR (83
vs 83%, P40.99). Moreover, the proportion of patients who
received an alloHSCT CR1 did not differ according to miR-3151
expression levels (n= 4 (15%) vs n= 38 (24%)) in patients with high
and low miR-3151 levels, respectively; P= 0.45).
A multivariate analysis confirmed high miR-3151 expression
as an independent adverse prognostic factor for OS (OR: 2.97;
95% CI: 1.78–4.93; Po0.001) and LFS (OR: 2.65; 95% CI: 1.43–4.90;
P= 0.002) in addition to other variables with prognostic value such
as age (OS, LFS), WBC count at diagnosis (OS), presence of FLT3-
ITD (OS), and NPM1 mutations (OS, LFS) (Table 2).
Higher miR-3151 expression was associated with worse prognosis
in both favorable and unfavorable molecular subgroups
We then analyzed the specific impact of miR-3151 expression on
outcome in the molecularly defined subgroups (FAVmol and
UNFAVmol). Among the 128 patients in the UNFAVmol subgroup,
high miR-3151 expression identified a subset of patients with a
very poor prognosis, with a shorter OS (5-year OS: 6 ± 10 vs
35± 8%; P= 0.011) and LFS (5-year LFS: 9 ± 15 vs 34 ± 10%;
P= 0.04) and a trend towards higher CIR (P= 0.1) (Figures 2a–c).
In the multivariate analyses, miR-3151 expression retained its
prognostic value in the UNFAVmol subgroup for OS (OR: 2.72; 95%
CI: 1.53–4.84; P= 0.001) and LFS (OR: 2.28; 95% CI: 1.10–4.72;
P= 0.026) (Table 2).
Despite the small size of the high miR-3151 expressers in the
FAVmol subgroup (n= 6 out of 50), high levels of miR-3151 were
also associated with shorter OS (5-year OS: 33 ± 38 vs 70 ± 12%;
P= 0.046) (Figure 2d), with a nonsignificant trend for LFS (P= 0.1).
Given the different expression level according to NPM1
mutation, prognostic impact was also analyzed separately in
NPM1mut and NPM1wt cohorts. Thus, among NPM1wt AML
patients, patients with higher miR-3151 levels showed a worse
outcome, with a shorter OS (5-years OS: 5 ± 10 vs 40 ± 10%;
P= 0.012) and LFS (5-year LFS: 7 ± 14 vs 36± 11%; P= 0.005) and a
higher CIR (5-years CIR: 77 ± 20 vs 52 ± 12%; P= 0.033)
(Supplementary Figures 1a–c).
The combination of miR-3151 and BAALC expression provides
additional independent prognostic value in IR-AML
In order to analyze the potential contribution to prognosis of the
combined expression of miR-3151 and the expression of its host
gene BAALC, we first studied the prognostic impact of BAALC
expression in this cohort. The optimal cut-off point was
determined using MaxStat (Figure 3a). Patients with higher BAALC
expression had poorer OS than those with lower expression levels
(5-year OS: 31 ± 10 vs 50 ± 10%; P= 0.01) (Figure 3b), poorer LFS
(5-year LFS: 32 ± 10 vs 54 ± 10%; P= 0.004) and higher CIR (5-year
CIR: 56 ± 12 vs 32± 12%; P= 0.0019).
Given the prognostic value shown by the expression level of
miR-3151 and BAALC as individual markers in the present study and
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Figure 1. miR-3151 and outcome in younger IR-AML patients. (a) The optimal cut-off level for miR-3151 expression as identified by the
MaxStat package. (b) Overall survival according to miR-3151 expression levels. (c) Leukemia-free survival according to miR-3151 expression
levels. (d) Cumulative incidence of relapse according to miR-3151 expression levels.
Table 2. Multivariate analyses for overall survival, leukemia-free survival and cumulative incidence of relapse in the overall series and in the
molecularly defined UNFAVmol subgroup
Variables P OR 95% CI P OR 95% CI
All patients UNFAVmol subgroup
Overall survival
Age o0.001 1.64 1.38–1.93 o0.001 1.60 1.32–1.91
Sex (male vs female) 0.28 1.24 0.83–1.84 0.18 1.35 0.87–2.10
WBC 0.006 1.21 1.06–1.38 0.08 1.14 0.98–1.32
FLT3-ITD 0.001 2.01 1.34–3.07 0.049 1.73 1.00–2.98
NPM1 mutated 0.017 0.60 0.39–0.91 0.22 0.96 0.38–1.25
miR-3151 levels (high vs low ) o0.001 2.97 1.78–4.93 0.001 2.72 1.53–4.84
Leukemia-free survival
Age 0.001 1.40 1.18–1.66 0.002 1.36 1.11–1.67
Sex (male vs female) 0.14 1.39 0.89–2.14 0.058 1.63 0.98–2.71
WBC 0.078 1.14 0.98–1.32 0.26 1.10 0.93–1.30
FLT3-ITD 0.081 1.53 0.94–2.46 0.706 1.14 0.56–2.32
NPM1 mutated 0.02 0.58 0.36–0.91 0.35 0.69 0.32–1.50
miR-3151 levels (high vs low) 0.002 2.65 1.43–4.90 0.026 2.28 1.10–4.72
Abbreviations: CI, confidence interval; OR, odds ratio; UNFAVmol, unfavorable molecular group. Age was analyzed with 10-year intervals and white blood cell
count at diagnosis using 50x109/l increments.
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the prognostic value of both factors in combination demonstrated
in a previous study performed by the CALGB study in older
patients,30 we then analyzed the prognostic impact of the
combination in our cohort of younger patients. High miR-3151
and high BAALC expression were defined as high-risk factors.
Patients were classified into three groups according to the number
of high-risk factors: low-risk group, 0 factors; intermediate-risk
group, 1 factor; and high-risk group, 2 factors. For the low-,
intermediate- and high-risk groups, 5-year OS was 56± 10%
33±10% and 7±14%, respectively (P=0.003) (Figure 3c), 5-year
LFS was 54± 12%, 37± 12%, and 1±18%, respectively (P=0.002)
(Figure 3d), and 5-year CIR was 33± 11%, 46±13%, and 90±37%,
respectively (Po0.001) (Figure 3e). The multivariate analyses
confirmed the combination as an independent prognostic factor
in OS (OR: 1.65; 95% CI: 1.14–2.39; P=0.007), LFS (OR: 2.05; 95% CI:
1.26–3.32; P=0.004), and CIR (OR: 1.99; 95% CI: 1.19–3.39; P=0.008),
after adjustment for other well-recognized molecular and clinical
prognostic markers (Supplementary Table 1).
Correlation of miR-3151 with miRNA expression
We had previously performed a comprehensive miRNA expression
analysis in 78 patients of this cohort10 using TaqMan Array Human
MicroRNA Set Cards v2.0 (AB). Remarkably, high expression of
miR-3151 was associated with a miRNA signature in the group of
patients with available miRNA profile, using BRB program from R.
This signature comprised the overexpression of miR-501-5p
(Po0.001), and downregulation of miR-590 (Po0.001),
miR-135a (Po0.001), miR-100* (P= 0.01), miR-186* (P= 0.01) and
let-7a* (P= 0.01) (Figure 4).
DISCUSSION
miRNAs are involved in diverse essential functional pathways both
in normal and neoplastic cells,31–33 and the expression of certain
miRNAs in CN-AML or IR-AML has been shown to have prognostic
relevance that can add useful information to molecular stratifica-
tion based on the analysis of NPM1, FLT3-ITD and CEBPA
Figure 2. miR-3151 and outcome in younger IR-AML patients according to molecularly defined subgroups (FAVmol and UNFAVmol). (a) Overall
survival according to miR-3151 expression levels in the UNFAVmol group. (b) leukemia-free survival according to miR-3151 expression levels in
the UNFAVmol group. (c) cumulative incidence of relapse according to miR-3151 expression levels in the UNFAVmol group. (d) Overall survival
according to miR-3151 expression levels in the FAVmol group.
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Figure 3. miR-3151 and BAALC expression and outcome in younger IR-AML patients. (a) The optimal cut-off level for BAALC expression as
identified by the MaxStat package. (b) Overall survival according to BAALC expression levels. (c) Overall survival according to the combination
of miR-3151 and BAALC expression levels. (d) leukemia-free survival according to the combination of miR-3151 and BAALC expression levels.
(e) Cumulative incidence of relapse according to the combination of miR-3151 and BAALC expression levels.
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mutations.13,19 Here we have first demonstrated the independent
prognostic value of miR-3151 expression and the combined
determination of miR-3151 and its host gene in a series of younger
IR-AML patients, both in the overall series and within molecularly
defined subgroups with a differentiated prognosis. These results
confirmed the prognostic impact of this miR-3151 previously
observed in a AML cohort of older patients.30 Our results in a
younger cohort might provide relevant clinical significance, by
identification of a subgroup of IR-AML patients with a worse
outcome who can be candidates to alloHSCT in an early phase.
Moreover, miR-3151 can be particularly useful among patients
without NPM1 mutations, who lack an universal molecular marker
for minimal residual disease monitoring as NPM1mut AML
patients.
IR-AML, the largest AML cytogenetic subgroup, comprises
patients with highly diverse prognosis, for whom the optimal
therapeutic strategies still largely unclear in several subgroups.
Currently prognostic stratification in these patients is based on the
analysis of a limited number of molecular markers, mainly NPM1,
FLT3-ITD and CEBPA, as recognized in the European LeukemiaNet
risk classification.1–4 Nonetheless the complex interaction of these
markers with many other gene mutations that can modify the final
prognostic impact, or the effect of intrinsic mutational character-
istics, such as, allelic burden or mutation site on protein function
and prognosis, make molecular risk stratification a highly complex
process.34 In this context, the investigation of alternative
biological AML features, such as gene or non-coding RNA
expression, might provide relevant additional information on
mechanisms of chemoresistance which might summarize the
resultant effect of diverse combination of gene mutations. Few
studies have identified several miRNA with prognostic value,
including a 4-miRNA signature described by our group in the
intermediate-risk AML cohort. miR-3151, described more recently,
was not included in this previous study; its particular location,
within a BAALC intron, a well-known AML prognostic factor,35 and
its prognostic impact observed in an elderly AML cohort,
prompted us to analyze its expression and prognostic effect in
younger IR-AML patients.
For this prognostic evaluation, we included different IR-AML
cytogenetic abnormalities beyond CN-AML, given the absence of
outcome difference between both IR-AML cytogenetic subgroups
(that is, normal an abnormal IR-AML karyotypes).2 Furthermore, IR-
AML usually comprise all cytogenetic aberrations not allocated to
good and poor-risk subgroups, and it is usually considered as the
same risk category for post-remission therapy decision, which in
younger patients includes the decision to perform an alloHSCT in
CR1. Remarkably, miR-3151 expression analysis revealed prog-
nostic value, with a detrimental effect among patients with higher
levels. Of note, miR-3151 was especially informative in the subset
of patients with an unfavorable genotype according to NPM1/
FLT3-ITD/CEBPA configuration and in the group of patients lacking
NPM1 mutations, identifying a subgroup with a particular poor
outcome. Availability of an additional prognostic tool in the
poorest prognosis subsets could be of evident clinical interest in
the subgroup of IR-AML patients not harboring a favorable
genotype (such as those defined in the European LeukemiaNet
favorable category). Moreover, prognostic value of miR-3151 value
was independent of other well-characterized prognostic factors
such as age, white blood cell count and gene mutations, and,
interestingly, retained its prognostic value when our previously
4-miRNA score was included in the analysis (Supplementary Table
2). Prognostic impact of miR-3151 was even enriched with the
simultaneous determination of BAALC which allowed us to build a
simple score based on these two factors.
Importantly, although several miRNAs have been identified as
prognostic markers in AML, their prognostic value has rarely been
confirmed by subsequent studies by different cooperative groups.
Here we have built on previous findings by CALGB showing the
importance of miR-3151 and BAALC expression in older CN-AML
patients23 and have validated their findings in younger IR-AML
patients. In a further step, we have also identified a miRNA
signature associated with higher expression of miR-3151, compris-
ing a distinctive expression level of several miRNAs, such as let-
7a*, miR-100*, miR-186*, miR-135a, miR-501-5p and miR-590.
We have shown in the present study that high expression of
miR-3151—both alone and in combination with high BAALC
expression—is an independent prognostic factor associated with
poor outcome in younger IR-AML patients. These results
confirmed for the first time the prognostic value of this miRNA
previously observed in an older IR-AML cohort, and suggest that
determination of its expression levels might improve risk
Figure 4. miRNA signature associated with high expression of miR-3151.
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stratification and post-remission treatment evaluation of younger
IR-AML.
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